NO845096L - Farmasoeytisk preparat for behandling av haartap - Google Patents

Farmasoeytisk preparat for behandling av haartap

Info

Publication number: NO845096L
Authority: NO; Norway
Prior art keywords: pharmaceutical preparation; topical; hair; growth; preparation according
Prior art date: 1983-04-19

Application number

NO845096A

Other languages

English (en)

Norwegian (no)

Inventor

Christopher Harry Mortimer

Original Assignee

Christopher Harry Mortimer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-04-19

Filing date

1984-12-18

Publication date

1984-12-18

1984-12-18 Application filed by Christopher Harry Mortimer filed Critical Christopher Harry Mortimer

1984-12-18 Publication of NO845096L publication Critical patent/NO845096L/no

Links

239000000825 pharmaceutical preparation Substances 0.000 title claims description 17
238000011282 treatment Methods 0.000 title description 27
201000004384 Alopecia Diseases 0.000 title description 17
230000003676 hair loss Effects 0.000 title description 13
208000024963 hair loss Diseases 0.000 title description 8
230000002280 anti-androgenic effect Effects 0.000 claims abstract description 36
239000000051 antiandrogen Substances 0.000 claims abstract description 34
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims abstract description 28
230000000699 topical effect Effects 0.000 claims abstract description 28
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims abstract description 27
229960002985 medroxyprogesterone acetate Drugs 0.000 claims abstract description 25
230000003779 hair growth Effects 0.000 claims abstract description 24
210000004761 scalp Anatomy 0.000 claims abstract description 20
239000000262 estrogen Substances 0.000 claims abstract description 13
239000005495 thyroid hormone Substances 0.000 claims abstract description 13
229940036555 thyroid hormone Drugs 0.000 claims abstract description 13
230000001076 estrogenic effect Effects 0.000 claims abstract description 12
230000009885 systemic effect Effects 0.000 claims abstract description 12
229940035722 triiodothyronine Drugs 0.000 claims abstract description 9
239000000203 mixture Substances 0.000 claims abstract description 6
230000001737 promoting effect Effects 0.000 claims abstract description 6
239000006210 lotion Substances 0.000 claims abstract description 5
239000002674 ointment Substances 0.000 claims abstract description 3
238000002360 preparation method Methods 0.000 claims description 33
229940088597 hormone Drugs 0.000 claims description 12
239000005556 hormone Substances 0.000 claims description 12
229940011871 estrogen Drugs 0.000 claims description 10
108090000790 Enzymes Proteins 0.000 claims description 7
102000004190 Enzymes Human genes 0.000 claims description 7
UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 claims description 5
229940124549 vasodilator Drugs 0.000 claims description 5
239000003071 vasodilator agent Substances 0.000 claims description 5
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical group IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims description 3
230000001195 anabolic effect Effects 0.000 claims description 3
229960000978 cyproterone acetate Drugs 0.000 claims description 3
229940034208 thyroxine Drugs 0.000 claims description 3
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims description 3
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 2
239000000674 adrenergic antagonist Substances 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims description 2
239000006071 cream Substances 0.000 claims description 2
239000012636 effector Substances 0.000 claims description 2
229930182833 estradiol Natural products 0.000 claims description 2
229960005309 estradiol Drugs 0.000 claims description 2
229960003843 cyproterone Drugs 0.000 claims 1
239000004615 ingredient Substances 0.000 claims 1
238000007911 parenteral administration Methods 0.000 claims 1
UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 abstract description 16
239000013543 active substance Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
210000004209 hair Anatomy 0.000 description 20
230000003803 hair density Effects 0.000 description 20
229950002007 estradiol benzoate Drugs 0.000 description 15
230000000694 effects Effects 0.000 description 14
241001615463 Trichogenes Species 0.000 description 13
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 12
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 12
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 12
229940095074 cyclic amp Drugs 0.000 description 12
239000002253 acid Substances 0.000 description 11
239000003098 androgen Substances 0.000 description 11
238000000034 method Methods 0.000 description 7
230000028327 secretion Effects 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 6
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 6
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
229960003604 testosterone Drugs 0.000 description 6
230000009467 reduction Effects 0.000 description 5
239000000126 substance Substances 0.000 description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
229940030486 androgens Drugs 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
210000003128 head Anatomy 0.000 description 4
BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 4
230000008569 process Effects 0.000 description 4
230000009897 systematic effect Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
AUYYCJSJGJYCDS-UHFFFAOYSA-N 2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid Chemical compound IC1=CC(CC(N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-UHFFFAOYSA-N 0.000 description 3
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
208000004631 alopecia areata Diseases 0.000 description 3
206010068168 androgenetic alopecia Diseases 0.000 description 3
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 3
230000008901 benefit Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
239000000186 progesterone Substances 0.000 description 3
229960003387 progesterone Drugs 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 2
JMSOBUJWXGTTLB-HNNXBMFYSA-N (2R)-2-amino-3-[4-(4-hydroxyphenoxy)phenyl]-2,3,3-triiodopropanoic acid Chemical compound IC([C@@](N)(C(=O)O)I)(C1=CC=C(C=C1)OC1=CC=C(C=C1)O)I JMSOBUJWXGTTLB-HNNXBMFYSA-N 0.000 description 2
WGAOZGUUHIBABN-UHFFFAOYSA-N 1-aminopentan-1-ol Chemical compound CCCCC(N)O WGAOZGUUHIBABN-UHFFFAOYSA-N 0.000 description 2
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 2
DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 2
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
230000001919 adrenal effect Effects 0.000 description 2
210000004100 adrenal gland Anatomy 0.000 description 2
230000001548 androgenic effect Effects 0.000 description 2
229960003473 androstanolone Drugs 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 2
229960002568 ethinylestradiol Drugs 0.000 description 2
210000003780 hair follicle Anatomy 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
229960004400 levonorgestrel Drugs 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
RLANKEDHRWMNRO-UHFFFAOYSA-M oxtriphylline Chemical compound C[N+](C)(C)CCO.O=C1N(C)C(=O)N(C)C2=C1[N-]C=N2 RLANKEDHRWMNRO-UHFFFAOYSA-M 0.000 description 2
230000001817 pituitary effect Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
230000004044 response Effects 0.000 description 2
238000009612 semen analysis Methods 0.000 description 2
BXJBFCKTIWRKMQ-MCDZGGTQSA-M sodium;(4ar,6r,7r,7as)-6-(6-aminopurin-9-yl)-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound [Na+].C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 BXJBFCKTIWRKMQ-MCDZGGTQSA-M 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
230000001629 suppression Effects 0.000 description 2
230000002381 testicular Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
210000001550 testis Anatomy 0.000 description 2
DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 description 1
PPWLAQVKIFDULF-UHFFFAOYSA-N 2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C=C1C1=CC=CC=C1 PPWLAQVKIFDULF-UHFFFAOYSA-N 0.000 description 1
ATXHVCQZZJYMCF-XUDSTZEESA-N Allylestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)CC=C)[C@@H]4[C@@H]3CCC2=C1 ATXHVCQZZJYMCF-XUDSTZEESA-N 0.000 description 1
206010001766 Alopecia totalis Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
101800000414 Corticotropin Proteins 0.000 description 1
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
206010011498 Cryptorchism Diseases 0.000 description 1
XURCMZMFZXXQDJ-UKNJCJGYSA-N Gestonorone caproate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 XURCMZMFZXXQDJ-UKNJCJGYSA-N 0.000 description 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
102000007399 Nuclear hormone receptor Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
206010039792 Seborrhoea Diseases 0.000 description 1
206010040880 Skin irritation Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229960002692 allylestrenol Drugs 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
239000002160 alpha blocker Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229960001231 choline Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
229960001380 cimetidine Drugs 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
229960000258 corticotropin Drugs 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
201000000160 cryptorchidism Diseases 0.000 description 1
108091007930 cytoplasmic receptors Proteins 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
239000011928 denatured alcohol Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
230000010339 dilation Effects 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 1
229960004913 dydrogesterone Drugs 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
229940014364 gestronol Drugs 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
239000007952 growth promoter Substances 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
229960002899 hydroxyprogesterone Drugs 0.000 description 1
229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
238000009533 lab test Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
238000007449 liver function test Methods 0.000 description 1
239000002075 main ingredient Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
229960004616 medroxyprogesterone Drugs 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229960003632 minoxidil Drugs 0.000 description 1
150000004712 monophosphates Chemical class 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
229940053934 norethindrone Drugs 0.000 description 1
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
229960001999 phentolamine Drugs 0.000 description 1
MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
229960003056 phentolamine mesylate Drugs 0.000 description 1
239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
235000003784 poor nutrition Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000003087 receptor blocking agent Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
230000036556 skin irritation Effects 0.000 description 1
231100000475 skin irritation Toxicity 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Birds (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Cosmetics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO845096A 1983-04-19 1984-12-18 Farmasoeytisk preparat for behandling av haartap NO845096L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB08310543A GB2138286B (en)	1983-04-19	1983-04-19	Pharmaceutical composition for the treatment of hair loss

Publications (1)

Publication Number	Publication Date
NO845096L true NO845096L (no)	1984-12-18

Family

ID=10541302

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO845096A NO845096L (no)	1983-04-19	1984-12-18	Farmasoeytisk preparat for behandling av haartap

Country Status (13)

Country	Link
EP (1)	EP0123528B1 (de)
JP (1)	JPS60501057A (de)
AT (1)	ATE29382T1 (de)
AU (1)	AU566833B2 (de)
CA (1)	CA1226524A (de)
DE (1)	DE3465879D1 (de)
GB (1)	GB2138286B (de)
GR (1)	GR81975B (de)
NO (1)	NO845096L (de)
NZ (1)	NZ207923A (de)
PT (1)	PT78456A (de)
WO (1)	WO1984004038A1 (de)
ZA (1)	ZA842986B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1985002543A1 (en) *	1983-12-12	1985-06-20	Kaszynski Edwin G	Hair growth modification
GB8403360D0 (en) *	1984-02-08	1984-03-14	Erba Farmitalia	Pharmaceutical compositions
US5116828A (en) *	1989-10-26	1992-05-26	Nippon Zoki Pharmaceutical Co., Ltd.	Pharmaceutical composition for treatment of osteoporosis
DE4100975A1 (de) *	1991-01-15	1992-07-16	Weuffen Wolfgang	Kosmetische oder pharmazeutische zubereitungen zur verbesserung der haarqualitaet und foerderung des haarwachstums
DE4237453C1 (de) *	1992-11-06	1993-08-19	Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
AU6434999A (en) *	1998-09-28	2000-04-17	Gavin Deon Petersen	Hair growth stimulant
US6680344B1 (en)	1999-06-01	2004-01-20	The University Of Texas Southwestern Medical Center	Method of treating hair loss using diphenylmethane derivatives
AU3711700A (en) *	1999-06-01	2000-12-18	University Of Texas Southwestern Medical Center, The	Biaryl compounds
AR018699A1 (es)	1999-06-01	2001-11-28	Procter & Gamble	Metodo para el tratamiento de la perdida del cabello el cual comprende administrar una composicion que comprende un compuesto el cual no afecta al corazon
AU3611500A (en) *	1999-06-01	2000-12-18	University Of Texas Southwestern Medical Center, The	Sulfur-containing thyroxane derivatives and their use as hair growth promotors
US6723717B1 (en) *	1999-06-01	2004-04-20	The University Of Texas Southwestern Medical Center	Sulfur-containing thyroxane derivatives and their use as hair growth promotors
JP2003500432A (ja) *	1999-06-01	2003-01-07	ザ・ユニバーシティ・オブ・テキサス・サウスウエスタン・メディカル・センター	ジフェニルエーテル誘導体を用いて脱毛症を処置する方法
BR0311568A (pt)	2002-07-05	2005-03-01	Unilever Nv	Método de tratamento de cabelo e uso de uma composição
US8288366B2 (en)	2006-06-20	2012-10-16	Chochinov Ronald H	Formulation for hair growth

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB782745A (en) *	1953-08-13	1957-09-11	Arthur Alfred Hellbaum	Improvements in or relating to pharmaceutical compositions
GB859546A (en) *	1956-05-29	1961-01-25	Arthur Alfred Hellbaum	Composition for treatment of the skin
GB874368A (en) *	1957-12-09	1961-08-02	Irwin Irville Lubowe	Improvements in anti-seborrheic and scalp preparations
FR6434M (de) *	1967-02-23	1968-11-04
GB1570524A (en) *	1976-03-11	1980-07-02	Unilever Ltd	Cosmetic
DE3003036A1 (de) *	1980-01-29	1981-07-30	Irmgard von Dr.med. 5300 Bonn Kistowski	Mittel zur verhinderung und beseitigung von glatzen

1983
- 1983-04-19 GB GB08310543A patent/GB2138286B/en not_active Expired
1984
- 1984-04-19 DE DE8484302686T patent/DE3465879D1/de not_active Expired
- 1984-04-19 WO PCT/GB1984/000135 patent/WO1984004038A1/en not_active Ceased
- 1984-04-19 JP JP59501698A patent/JPS60501057A/ja active Pending
- 1984-04-19 AT AT84302686T patent/ATE29382T1/de active
- 1984-04-19 PT PT78456A patent/PT78456A/pt not_active IP Right Cessation
- 1984-04-19 ZA ZA842986A patent/ZA842986B/xx unknown
- 1984-04-19 GR GR74480A patent/GR81975B/el unknown
- 1984-04-19 CA CA000452426A patent/CA1226524A/en not_active Expired
- 1984-04-19 AU AU28284/84A patent/AU566833B2/en not_active Ceased
- 1984-04-19 NZ NZ207923A patent/NZ207923A/xx unknown
- 1984-04-19 EP EP84302686A patent/EP0123528B1/de not_active Expired
- 1984-12-18 NO NO845096A patent/NO845096L/no unknown

Also Published As

Publication number	Publication date
GR81975B (de)	1984-12-12
AU566833B2 (en)	1987-10-29
EP0123528A1 (de)	1984-10-31
NZ207923A (en)	1988-07-28
GB2138286A (en)	1984-10-24
ZA842986B (en)	1985-06-26
CA1226524A (en)	1987-09-08
JPS60501057A (ja)	1985-07-11
ATE29382T1 (de)	1987-09-15
DE3465879D1 (en)	1987-10-15
WO1984004038A1 (en)	1984-10-25
AU2828484A (en)	1984-11-07
EP0123528B1 (de)	1987-09-09
GB2138286B (en)	1986-10-08
GB8310543D0 (en)	1983-05-25
PT78456A (en)	1984-05-01

Publication	Publication Date	Title
Lynfield	1960	Effect of pregnancy on the human hair cycle
Strauss et al.	1962	The effect of androgens and estrogens on human sebaceous glands
NO845096L (no)	1984-12-18	Farmasoeytisk preparat for behandling av haartap
ANDREYKO et al.	1986	Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin)
US20100317631A1 (en)	2010-12-16	Gel Composition and Transcrotal Application of a Composition for the Treatment of Hypogonadism
CN102159179A (zh)	2011-08-17	防止、治疗脱发或促进毛发生成的成分
JPH09295921A (ja)	1997-11-18	育毛・養毛剤
EP0998907B1 (de)	2004-01-14	Adenosin enthaltendes Haartonikum
CN116803391B (zh)	2025-11-28	Wez系列化合物在制备预防或/和治疗脱发产品中的用途
NO860203L (no)	1986-01-21	Behandling av kvinners haartap.
SK13422000A3 (sk)	2001-05-10	Liečivo na prevenciu a/alebo liečenie karcinómu pŕs, ktoré obsahuje inhibítor steroidnej aromatázy
Sinha et al.	1969	Relationship of pituitary prolactin and LH to mammary and uterine growth of pubertal rats during the estrous cycle
US20070116658A1 (en)	2007-05-24	Hair tonic composition
US6204258B1 (en)	2001-03-20	Method of treating alopecia
Hajdúch et al.	2006	Current therapies of female androgenetic alopecia and use of fluridil, a novel topical antiandrogen
AU771256B2 (en)	2004-03-18	Medicaments comprising relaxin and their use
EP0451156A1 (de)	1991-10-16	Minoxidil und vasokonstriktorzusammensetzungen zur behandlung von alopecia
US6344448B1 (en)	2002-02-05	Composition for the treatment of hair loss
EP0163489A1 (de)	1985-12-04	Behandlung von Haarausfall bei Frauen
JP3496896B2 (ja)	2004-02-16	養毛剤及び毛髪用化粧料
Jagadeesan et al.	2024	Disorders of Hair in Pregnancy and Postpartum
GB2131292A (en)	1984-06-20	Progestational pharmaceutical formulations
Cox et al.	1975	Perturbations of the human menstrual cycle by oxymetholone
US20250120972A1 (en)	2025-04-17	Pharmacy compounded prescription compositions for hair growth
Sharma et al.	2000	Management of androgenetic alopecia